Last updated: February 20, 2026
What is RENOGRAFIN-76?
RENOGRAFIN-76 is an iodinated contrast agent primarily used in radiology. It is formulated for intravascular imaging procedures, such as angiography, to visualize blood vessels. Its chemical composition provides high radiopacity, enabling clear imaging with minimal doses.
Market Overview
The global contrast media market was valued at approximately USD 4.7 billion in 2022. It is projected to grow at a Compound Annual Growth Rate (CAGR) of 4.2% through 2030, driven by increased diagnostic imaging procedures and aging populations.
Key market segments include:
- Intravenous contrast agents: 55%
- Intra-arterial contrast agents: 30%
- Other applications: 15%
Renografin-76 specifically falls under intra-arterial agents; its market share is modest but stable.
Competitive Landscape
Major competitors include:
| Company |
Product Names |
Market Share |
Notes |
| GE Healthcare |
Omnipaque, Isovue |
40% |
Extensive global distribution |
| Bracco |
Isovue, Optiray |
25% |
Strong in Europe, Asia |
| Bayer |
Lumirem, Ultravist |
15% |
Focus on specialized imaging |
| Other |
Iohexol, Iodixanol |
20% |
Niche and regional players |
Renografin-76 has limited market share compared to these dominant products.
Regulatory Environment
- FDA Approval: Approved for intravascular imaging procedures.
- EMA Policies: Similar approvals in Europe.
- Biosimilar Competition: Minimal for contrast agents; barriers due to safety and efficacy requirements.
Patent and IP Position
- RENOGRAFIN-76 patents expired in key markets by 2015.
- No existing patent protections limit production; the product faces generic competition.
Commercial and Regulatory Challenges
- Safety profile concerns: Potential nephrotoxicity and iodine-related adverse effects.
- Environmental impact: Disputes over iodine-based contrast agents' elimination and effects on wastewater.
- Regulatory restrictions: Increased restrictions on contrast agent use due to adverse event reports.
Investment Fundamentals
Revenue and Profitability
- Current Sales: Estimated USD 50-100 million annually, primarily in settled contracts.
- Margins: Estimated gross margin at ~50%, net profit margins around 10-15% due to regulatory and marketing costs.
- Pricing: Competitive, with price points similar to other iodinated contrast agents (~USD 10-15 per dose).
Commercial Viability
- Limited growth prospects due to patent expiration.
- Market saturation with existing products.
- Commercial success depends on branding, distribution agreements, and patenting new formulations.
R&D and Pipeline
- No significant R&D pipeline reported.
- Potential for formulation revision to enhance safety or reduce iodine dosage.
Regulatory Outlook
- Enhanced safety regulations could limit use.
- Opportunities in emerging markets with underdeveloped regulatory landscapes.
Risks
- Market Saturation: High competition makes price and volume growth challenging.
- Regulatory Risks: Stricter safety requirements could restrict use.
- Environmental and Safety Image: Negative perceptions may decrease adoption.
Investment Outlook
- Short-term (1-3 years): Limited growth due to market saturation and patent expiration.
- Medium-term (3-5 years): Potential niche applications if reformulated for better safety.
- Long-term (5+ years): Low likelihood of significant market share gains unless innovation occurs.
Key Takeaways
- RENOGRAFIN-76 is a mature, generic contrast agent with declining market share.
- Current revenue streams are stable but limited, with margins around 10-15%.
- Major competitors command significant market share with extensive portfolios.
- Patent expiry exposes the product to generic competition.
- Regulatory environment and safety concerns pose ongoing risks.
- Future growth depends on reformulation, regulatory navigation, or market expansion in underserved regions.
FAQs
1. What factors threaten the future of RENOGRAFIN-76?
Patent expiration leading to generic competition, safety concerns, and regulatory restrictions.
2. Can RENOGRAFIN-76 regain market share?
Regaining share requires product reformulation or targeted marketing in emerging markets.
3. Are there opportunities for innovation within its formulation?
Yes, reformulation to reduce iodine dosage or enhance safety may extend its viability.
4. How does the competitive landscape impact potential investment?
Market dominance by GE and Bracco makes entry or expansion challenging without differentiation.
5. What regulatory trends could influence RENOGRAFIN-76?
Stricter safety evaluations and environmental regulations could limit use or increase compliance costs.
References
- MarketsandMarkets. (2023). Contrast media market analysis.
- FDA. (2022). Approved contrast agents.
- European Medicines Agency. (2022). Radiology contrast media regulation.
- Grand View Research. (2022). Contrast Media Market Size & Trends.
- Industry reports on contrast media patent expiration timelines.
